ea0041gp117 | Endocrine Tumours | ECE2016
Oduwole Olayiwola
, Poliandri Ariel
, Rawson Phil
, Rahman Nafis
, Koechling Wolfgang
, Huhtaniemi Ilpo
Gonadotropin-releasing hormone (GnRH) analogues are now the standard hormonal treatment for prostate cancer. A fundamental difference between GnRH agonist and antagonist treatment is the permanent suppression of both gonadotropins (LH and FSH) by antagonist, while a rebound in FSH is associated with agonist treatment. The benefits of antagonist include the immediate onset of action and profound long-term suppression of FSH, suggested to be an independent growth factor in prost...